Nearly 200 deaths and over 150,000 adverse reactions have been linked to anti-obesity drugs Mounjaro, Wegovy, Ozempic, and Saxenda in the UK, according to data from the MHRA Yellow Card scheme.
Bank of America CEO'su Brian Moynihan, bankanın 211 bin çalışanı için sağlanan sağlık sigortası kapsamında GLP-1 kilo verme ilaçlarına yıllık 250 milyon dolardan fazla harcadıklarını ve bunun iyi bir yatırım olduğunu belirtti.
Eli Lilly reported better-than-expected Q2 2026 results with revenue up 48% to $22.97 billion, driven by its GLP-1 portfolio including Zepbound and Mounjaro, prompting the company to raise its full-year revenue guidance.
Bank of America spends over $250 million annually covering GLP-1 weight loss drugs for employees, accounting for roughly 13% of its $2 billion healthcare budget, CEO Brian Moynihan told CNBC.
U.S.-traded shares of Novo Nordisk fell 6% Tuesday after the Danish drugmaker issued updated 2026 guidance and reported second-quarter financial metrics, citing intensifying competition and lower U.S. prices.
Dermatologists in India report a rise in hair loss, often telogen effluvium, among GLP-1 weight-loss drug users, particularly those experiencing rapid weight reduction without medical supervision. Nutritional deficiencies and metabolic stress are cited as causes, with a Saudi Arabian study finding 70.4% of users reported shedding.
Growing demand for mini fridges for beauty products and GLP-1 medication is reshaping homes, driven by the wellness industry and weight-loss drugs. This trend spans luxury to budget markets, despite dermatological skepticism for most skincare products.
The "proteinmaxxing" trend and GLP-1 weight-loss medications are driving up demand for whey protein, a vital ingredient in infant formula. This has led to a 4.8% increase in UK formula prices, raising concerns about affordability for families and prompting calls for government-imposed price or profit caps.
US retail giants like Walmart, Costco, CVS, and Amazon are leveraging direct-to-consumer GLP-1 weight-loss drug programs to acquire long-term customer relationships, as employers increasingly drop coverage. This strategy aims to drive loyalty and cross-selling opportunities.
A woman recounts her struggle with body image and unhealthy dieting before her wedding. She later finds liberation and physical strength by adopting a "bulking" regimen, focusing on muscle gain and progressive overload, challenging ingrained societal beauty standards despite internal anxieties.
Avustralya Şifalı Ürünler İdaresi (TGA), Tip-2 diyabet ve obezite tedavisinde kullanılan GLP-1 ilaçlarının nadir görülen "arteritik olmayan anterior iskemik optik nöropati (NAION)" hastalığına yol açabileceği konusunda uyardı. NAION'un körlük dahil kalıcı görme bozukluğuna neden olabileceği belirtilirken, kullanıcıların görme kaybı yaşamaları halinde ilacı bırakıp acilen sağlık kuruluşuna başvurması gerektiği vurgulandı. TGA, 36 vaka tespit etti.
Avustralya Şifalı Ürünler İdaresi (TGA), Tip-2 diyabet ve obezite tedavisinde kullanılan GLP-1 ilaçlarının nadir görülen "arteritik olmayan anterior iskemik optik nöropati (NAION)" hastalığına yol açabileceği konusunda uyardı. NAION, kalıcı görme bozukluğuna ve körlüğe neden olabilir; TGA, bu ilaçlarla bağlantılı 36 NAION vakası tespit edildiğini belirtti.
Australia's Therapeutic Goods Administration (TGA) has warned about a "rare but severe" eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to type 2 diabetes and obesity treatments like Ozempic and Mounjaro. The warning, based on 36 reported cases, advises patients to seek urgent medical attention for sudden vision loss but not to stop treatment without consulting a doctor.
A news briefing highlights the Christian Brothers' agreement to compensate abuse survivors, new US trade tariffs on Australian exports, and domestic concerns over an impending El Niño summer, alongside other headlines including a Socceroos star's alleged drug test and airport advertising disputes.
Australia's TGA has issued a safety warning for GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, linking them to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare eye disorder causing potential permanent vision loss. Experts advise caution but not panic, stressing consultation with prescribers.
Pennsylvania Üniversitesi araştırmacıları, Ozempic ve Wegovy gibi GLP-1 ilaçlarının saç dökülmesi riskini SGLT-2 ve DPP-4 inhibitörlerine kıyasla daha yüksek buldu. Çalışma, hızlı kilo kaybı ve besin eksikliğinin geçici saç dökülmesine yol açabileceğini belirtiyor.
İsviçre merkezli Galderma'nın CEO'su Flemming Ørnskov, GLP-1 ilaçları kaynaklı hızlı kilo kaybı sonrası yüzde oluşan sarkma ve hacim kaybına yönelik estetik tedavilere talebin arttığını belirtti. Şirketin ABD satışları yüzde 32 artarken, bu durumun önemli bir fırsat olduğu vurgulandı.
Galderma CEO Flemming Ørnskov stated that the increased use of weight-loss drugs like Ozempic and Wegovy presents a "significant opportunity" for the aesthetics company, particularly in mitigating facial sagging. The company reported nearly 25% sales growth, with U.S. growth outpacing other regions at 32%.
Danish pharmaceutical giant Novo Nordisk is suing US-based Eli Lilly in a New Jersey court for "false and misleading" advertisements. Novo Nordisk alleges Eli Lilly used "outdated studies" to compare GLP-1 agonist drugs like Wegovy and Ozempic to Mounjaro and Zepbound, causing confusion.
Two US biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are testing experimental GLP-1 weight-loss treatments for overweight cats, aiming to bring the blockbuster drug class into pet medicine amidst a growing pet obesity problem and increasing owner spending on pet health.
GLP-1類藥物（瘦瘦針）雖受歡迎，但停藥後復胖是隱憂。研究顯示停藥一年內恐回彈近6成，平均每月回升0.8公斤。醫師強調，減重關鍵在於療程中建立健康代謝習慣，而非藥物依賴。透過遊戲化健康管理如皮克敏手遊，可提升步行習慣，輔助建立穩定生活型態。
Vivani Medical is developing a GLP-1 implant for long-term weight loss maintenance, potentially reducing side effects and injection fatigue. The device, an experimental semaglutide implant, aims for twice-yearly or annual administration, complementing existing GLP-1 treatments. However, it faces clinical trials, regulatory hurdles, and questions about cost and physician adoption.
Giyilebilir teknoloji şirketi WHOOP'un araştırması, zayıflama iğnesi kullananlarda kalp ritminde ek yük ve stres oluştuğunu gösterdi. Haftada 30 dakika egzersiz ve ağırlık antrenmanı bu riskleri azaltıyor.
Ozivy, fabricado pela EMS, foi incluído na Lista de Medicamentos de Referência da Anvisa. Isso permite que outros laboratórios desenvolvam versões genéricas ou similares do medicamento no futuro, que tem o mesmo princípio ativo do Ozempic.
